Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib

BACKGROUND: Acute myeloid leukaemia (AML) is an aggressive blood cancer. In approximately 30% of the cases, driver mutations in the FLT3 gene are identified. FLT3 inhibitors are used in treatment of such patients together with cytotoxic drugs or (in refractory AML) as single agents. Unfortunately, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jingmei, Lindström, H. Jonathan G., Friedman, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033742/
https://www.ncbi.nlm.nih.gov/pubmed/33832508
http://dx.doi.org/10.1186/s12935-021-01856-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033742/
https://www.ncbi.nlm.nih.gov/pubmed/33832508
http://dx.doi.org/10.1186/s12935-021-01856-5

Ejemplares similares